CCL17 and Alzheimer disease: The combined mixed model analysis (Table 4), which also accounted for longitudinal changes showed that Eotaxin-3, TARC and PYY may represent a suitable stable biomarker for differentiating between HC and AD (p = 0.07, p = 0.06 and p = 0.07, respectively).